Table 1 Baseline characteristics of EOC patients in the training and test sets
Characteristics | All patients (n = 144) | Training set (n = 101) | Test set (n = 43) | P-value |
|---|---|---|---|---|
Age (years) | 57.0 (50.0, 66.8) | 58.0 (50.0, 67.5) | 54.0 (49.0, 63.0) | 0.111 |
Menopause | 0.495 | |||
Yes | 106 (73.6%) | 76 (75.2%) | 30 (69.8%) | |
No | 38 (26.4%) | 25 (24.8%) | 13 (30.2%) | |
FIGO stage | 0.281 | |||
I-II | 34 (23.6%) | 22 (21.8%) | 13 (30.2%) | |
III-IV | 110 (76.4%) | 79 (78.2%) | 30 (69.8%) | |
CA125 (U/mL) | 375.9 (166.0, 719.2) | 733.2 (264.1, 1396.5) | 673.0 (224.9, 1720.0) | 0.991 |
Residual tumor | 0.132 | |||
> 1 cm | 84 (58.3%) | 63 (62.4%) | 21 (48.8%) | |
≦ 1 cm | 60 (41.7%) | 38 (37.6%) | 22 (51.2%) | |
Tumor location | 0.133 | |||
Bilateral | 94 (65.3%) | 62 (61.4%) | 32 (74.4%) | |
Unilateral | 50 (34.7%) | 39 (38.6%) | 11 (25.6%) | |
Tumor diameter (mm) | 79.3 (56.1, 114.8) | 78.6 (53.5, 113.0) | 86.3 (60.0, 116.0) | 0.482 |
Ascites | 0.083 | |||
Yes | 122 (84.7%) | 89 (88.1%) | 33 (76.7%) | |
No | 22 (15.3%) | 12 (11.9%) | 10 (23.3%) | |
Tumor characteristics | 0.400 | |||
Mainly cystic | 34 (23.6%) | 24 (23.8%) | 10 (23.3%) | |
Solid | 64 (44.4%) | 48 (47.5%) | 16 (37.2%) | |
Mixed cystic and solid | 46 (32.0%) | 29 (28.7%) | 17 (39.5%) | |
Enhanced CT value | 61.5 (53.6, 67.0) | 61.5 (52.8, 66.6) | 61.4 (54.6, 68.9) | 0.389 |
Disease progression | 0.841 | |||
Yes | 92 (63.9%) | 64 (63.4%) | 28 (65.1%) | |
No | 52 (36.1%) | 37 (36.6%) | 15 (34.9%) | |
PFS (days) | 642.5 (320.0, 1296.0) | 596.0 (269.5, 1324.0) | 869.0 (363.0, 1297.0) | 0.457 |